The most advanced clinical programs at Precigen (PGEN) — known as PRGN-3005 UltraCAR-T and PRGN-3006 UltraCAR-T — have both delivered proof of concept data in cancer patients recently, asserts biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.

The company has developed an innovative & revolutionary UltraCAR-T platform. Precigen's most advanced clinical programs — PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T — have both delivered proof of concept data in cancer patients recently.

The UltraCAR-T platform is fundamentally differentiated from the competition and we believe will disrupt the cancer CAR-T treatment landscape by increasing patient access through rapid manufacturing, lower manufacturing-related costs, and improved outcomes using advanced technologies for precise tumor targeting and control of the immune system.

The key driver of improved UltraCAR-T performance is the expression of membrane-bound interleukin-15, or mbIL15 which allows for much less expensive in-house manufacturing of CAR-T therapies.

IL-15 is a master regulator cytokine that promotes T-cell activation and expansion as well as survival of memory T cells to enhance anti-tumor response.

Expression of mbIL15 is shown to enhance in vivo expansion in the presence of tumor antigens and prevent UltraCAR-T cell exhaustion leading to longer persistence and an enduring anti-tumor response that outlasts conventional CAR-T cells.

MoneyShow’s Top 100 Stocks for 2021

The top performing newsletter advisors and analyst are back, and they just released their best stock ideas for 2021. Get your FREE copy of MoneyShow’s 2021 Top Picks report here and see why the nation's leading investment experts believe these stocks will significantly outperform the market in 2021.

ActoBio, a wholly-owned subsidiary of Precigen, announced new data for the Phase 1b monotherapy and Phase 2a combination study of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of early-onset Type 1 Diabetes (T1D). While early in development, AG019 has the potential to be a game changer for T1D.

With three programs in human clinical trials the company is poised for significant news flow in 2021.  The UltraCAR-T program is coming along incredibly well and is demonstrating that PGEN can manufacture CAR-Ts overnight in the hospital to significantly reduce expenses.

We are also more than excited to see the preliminary anti-tumor activity with ULTRA-CAR-T as CAR-Ts have a tendency to work right away or not at all.

Precigen has emerged as one of our favorite stocks, and in our view is still largely ignored by institutions, and we expect a very strong 2021. The stock is a "buy" under $12 with a target price of $24 per share. 

Subscribe to The Medical Technology Stock Letter here…